[ET Net News Agency, 21 October 2020] Sino Biopharmaceutical Limited (01177) said the
anti-tumour drug "Capecitabine Tablets" (brand name: Shoufu) of the group has obtained the
notice of approval of supplemental applications issued by the National Medical Products
Administration of the People's Republic of China and has passed the Consistency of Quality
and Efficacy Evaluation for Generic Drugs. The indications of Shoufu are for the adjuvant
chemotherapy of colon cancer, combination chemotherapy for colorectal cancer and breast
cancer, single-agent chemotherapy for breast cancer, and adjuvant therapy for gastric
cancer.
Capecitabine is an oral cytotoxic agent with selective activity on tumour cells. It has
no cytotoxicity, but is converted into 5-fluorouracil (5-FU) under the action of enzymes
in the body to exert anti-tumour effects. (RC)